{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:00:46Z","timestamp":1768086046056,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,10]]},"DOI":"10.7759\/cureus.101236","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T15:05:27Z","timestamp":1768057527000},"source":"Crossref","is-referenced-by-count":0,"title":["Valproic Acid and Famotidine Drug-Drug Interaction: Report of a Pediatric Case"],"prefix":"10.7759","author":[{"given":"Mirei","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelease","family":"O'Bryant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Mirajkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Valproic Acid","author":"Rahman M","year":"2024","unstructured":"Rahman M, Awosika AO, Nguyen H. Valproic Acid. StatPearls Publishing, Treasure Island; 2024."},{"key":"ref2","article-title":"Valproate Toxicity","author":"Patel AR","year":"2024","unstructured":"Patel AR, Nagalli S. Valproate Toxicity. StatPearls Publishing, Treasure Island; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen X","year":"2001","unstructured":"Wen X, Wang JS, Kivist\u00f6 KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001, 52:547-53. 10.1046\/j.0306-5251.2001.01474.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01171-w","article-title":"Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review","volume":"61","author":"Lin K","year":"2022","unstructured":"Lin K, Cao VF, Au C, Dahri K. Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review. Clin Pharmacokinet. 2022, 61:1345-63. 10.1007\/s40262-022-01171-w","journal-title":"Clin Pharmacokinet"},{"key":"ref5","unstructured":"Label. Valproic Acid. NIH Library of Medicine Daily Med. (2025). Accessed: 2025: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8051ad62-3b6e-461e-8090-60f5c0a904f4."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00021.x","article-title":"Review article: drug interactions with agents used to treat acid-related diseases","volume":"13 Suppl 3","author":"Humphries TJ","year":"1999","unstructured":"Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999, 13 Suppl 3:18-26. 10.1046\/j.1365-2036.1999.00021.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","article-title":"Famotidine","author":"Patel P","year":"2025","unstructured":"Patel P, Ahlawat R. Famotidine. StatPearls Publishing, Treasure Island; 2025."},{"key":"ref8","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury - Famotidine","year":"2018","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury - Famotidine  .  National Institute of Diabetes and Digestive and Kidney Diseases, 2018."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2013.11.006","article-title":"Interaction of famotidine, an H2 histamine receptor antagonist, with conventional antiepileptic drugs in mice","volume":"66","author":"\u015awi\u0105der MJ","year":"2014","unstructured":"\u015awi\u0105der MJ, Czuczwar SJ. Interaction of famotidine, an H2 histamine receptor antagonist, with conventional antiepileptic drugs in mice. Pharmacol Rep. 2014, 66:485-91. 10.1016\/j.pharep.2013.11.006","journal-title":"Pharmacol Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.635149","article-title":"2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report","volume":"49","author":"Bronstein AC","year":"2011","unstructured":"Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol. 2011, 49:910-41. 10.3109\/15563650.2011.635149","journal-title":"Clin Toxicol"},{"key":"ref11","article-title":"Amantadine","author":"Chung C","year":"2023","unstructured":"Chung C, Ramphul K. Amantadine . StatPearls Publishing, Treasure Island; 2023."},{"key":"ref12","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury - Cyproheptadine","year":"2017","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury - Cyproheptadine. National Institute of Diabetes and Digestive and Kidney Diseases, 2017."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(81)80489-1","article-title":"Hyperammonemia with valproic acid therapy","volume":"99","author":"Coulter DL","year":"1981","unstructured":"Coulter DL, Allen RJ. Hyperammonemia with valproic acid therapy. J Pediatr. 1981, 99:317-9. 10.1016\/s0022-3476(81)80489-1","journal-title":"J Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1985.tb00854.x","article-title":"Valproate: an updated review","volume":"72","author":"Gram L","year":"1985","unstructured":"Gram L, Bentsen KD. Valproate: an updated review. Acta Neurol Scand. 1985, 72:129-39. 10.1111\/j.1600-0404.1985.tb00854.x","journal-title":"Acta Neurol Scand"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1080\/15563650802178136","article-title":"Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management","volume":"46","author":"Manoguerra AS","year":"2008","unstructured":"Manoguerra AS, Erdman AR, Woolf AD, et al.. Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2008, 46:661-76.","journal-title":"Clin Toxicol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0196-0644(89)80220-3","article-title":"Central nervous system manifestations of a valproic acid overdose responsive to naloxone","volume":"18","author":"Alberto G","year":"1989","unstructured":"Alberto G, Erickson T, Popiel R, Narayanan M, Hryhorczuk D. Central nervous system manifestations of a valproic acid overdose responsive to naloxone. Ann Emerg Med. 1989, 18:889-91. 10.1016\/s0196-0644(89)80220-3","journal-title":"Ann Emerg Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/15563650902752376","article-title":"Carnitine in the treatment of valproic acid-induced toxicity","volume":"47","author":"Lheureux PE","year":"2009","unstructured":"Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol. 2009, 47:101-11. 10.1080\/15563650902752376","journal-title":"Clin Toxicol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/cc3742","article-title":"Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?","volume":"9","author":"Lheureux PE","year":"2005","unstructured":"Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?. Crit Care. 2005, 9:431. 10.1186\/cc3742","journal-title":"Crit Care"},{"key":"ref19","unstructured":"Carnitine supplements (Levocarnitine). drug information. UptoDate\u00ae Lexidrug\u2122 (restricted access). (2025). Accessed: 02\/10\/2025: https:\/\/www.uptodate.com\/contents\/carnitine-supplements-levocarnitine-drug-information."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.09.011","article-title":"Meropenem as an antidote for intentional valproic acid overdose","volume":"38","author":"Thomas C","year":"2020","unstructured":"Thomas C, Priano J, Smith TL. Meropenem as an antidote for intentional valproic acid overdose. Am J Emerg Med. 2020, 38:690.e1-2. 10.1016\/j.ajem.2019.09.011","journal-title":"Am J Emerg Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020257","article-title":"Carbapenems as antidotes for the management of acute valproic acid poisoning","volume":"17","author":"Perkovi\u0107 Vuk\u010devi\u0107 N","year":"2024","unstructured":"Perkovi\u0107 Vuk\u010devi\u0107 N, Mijatovi\u0107 Jovin V, Vukovi\u0107 Ercegovi\u0107 G, Antunovi\u0107 M, Kele\u010devi\u0107 I, \u017divanovi\u0107 D, Vu\u010dini\u0107 S. Carbapenems as antidotes for the management of acute valproic acid poisoning. Pharmaceuticals. 2024, 17:257. 10.3390\/ph17020257","journal-title":"Pharmaceuticals"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2021.09.033","article-title":"Treatment of valproic acid overdose with meropenem in an epileptic patient","volume":"53","author":"Cunningham D","year":"2022","unstructured":"Cunningham D, Clark K, Lord K. Treatment of valproic acid overdose with meropenem in an epileptic patient. Am J Emerg Med. 2022, 53:284.e1-3. 10.1016\/j.ajem.2021.09.033","journal-title":"Am J Emerg Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383497-valproic-acid-and-famotidine-drug-drug-interaction-report-of-a-pediatric-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T15:05:28Z","timestamp":1768057528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383497-valproic-acid-and-famotidine-drug-drug-interaction-report-of-a-pediatric-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.101236","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,10]]}}}